Protocol Ledger

NCT04088396 · Phase III · ACTIVE NOT RECRUITING

A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)

Interventional Phase III clinical trial protocol NCT04088396 sponsored by Eli Lilly and Company in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-02-12 Enrollment: 58 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04088396
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)58 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04088396
Protocol FieldVerified Registry Value
NCT IdentifierNCT04088396
Consolidated Lead SponsorEli Lilly and Company
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment58 participants (ESTIMATED)
Registered Start Date2020-02-12
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04088396
Hospital Research SiteLocationSite Profile
UZ GentGhent, BelgiumOpen Hospital Dossier ->
Hospital de Clinicas de Porto AlegrePorto Alegre, BrazilOpen Hospital Dossier ->
Vseobecna fakultni nemocnice v PrazePrague, CzechiaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI